RESEARCH TRIANGLE PARK, NC – Mi-Co and its partners, the University of North Carolina (UNC) Breast Imaging Section, Health Decisions and American College of Radiology Imaging Network (ACRIN) were awarded a $750,000 Small Business Innovation Research (SBIR) contract by the National Institute of Health’s National Cancer Institute.
Mi-Co will utilize its Mi-Forms product suite in order to study the impact of the digital writing, data capture software in a clinical trials setting.
In the Phase I study, the research team assessed alternative pen based methods of recording clinical trial data through the digital writing process.
In the second phase of the program, Mi-Co, ACRIN and UNC will deploy Mi-Forms with Digital Pens and Tablet PCs on a targeted basis for a clinical trial that is being conducted at UNC.
Dr. Etta Pisano at UNC was optimistic about the use of the Mi-Co technology in the clinical trial setting. “Mi-Co’s technology is very exciting because it will make participation in clinical trials easier and more acceptable to very busy clinicians. The digital writing techniques we have been testing are much easier to use than a keyboard and mouse. In addition, these techniques will provide more accurate data because of the system’s ability to check for data errors throughout the process from data capture to data communication.”
“The entire project team is truly excited about this award. We will see the entire system working in a very demanding environment because of FDA regulations for clinical trials software and processes and the very high data quality standards of the ACRIN organization,” said Dr. Greg Clary, Principal Investigator and CTO at Mi-Co.
In addition to the specific assessment of data capture and digital writing solutions that turn handwriting into electronic text, the study also includes implementing the transfer of data from Mi-Forms to ACRIN’s Oracle backend system via XML.
www.mi-corporation.com
Related Stories:
- Novartis, NC-based AlphaVax ink deal worth $20M plus
- RTP’s AlphaVax starts clinical trials
- NC’s Serenex starts clinical trial of cancer inhibitor
- SBIR funding success in RTP
- Miami’s Opko Health shutters clinical trial
© 2004, TechJournal. All rights reserved.
